Allergies News and Research

Latest Allergies News and Research

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

AllOne Health(SM) and Connectyx Technologies Holdings Group, Inc. (Pink Sheets: CTYX) today announced a partnership that will allow consumers to view and manage health information on the Web, via portable USB storage devices and through their mobile phones, with one, secure step. A package including both companies' products will be sold in retail stores across the U.S. in December.

2 Nov 2009

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.

2 Nov 2009

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

The Lupus Research Institute (LRI) and its National Coalition of state and local lupus organizations congratulate Human Genome Sciences (HGS) and GlaxoSmithKline for achieving an historical landmark - the second positive phase 3 clinical trial of Benlysta (belimumab), the first successfully tested new drug developed specifically for people with systemic lupus.

2 Nov 2009

Scientists report a major step forward in the development of an effective therapy against Nipah virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), Australian Animal Health Laboratory and National Cancer Institute, a component of the National Institutes of Health, reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

31 Oct 2009

New tools and interventions can help in eradicating malaria

Although malaria has been controlled in many local and regional populations, the permanent elimination of malaria parasites throughout the world remains an elusive goal, and the disease continues to claim nearly one million lives each year.

31 Oct 2009

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. GBS is the most common cause of sepsis and meningitis in newborns in the United States, according to the Centers for Disease Control and Prevention (CDC). It can also cause severe illness in pregnant women, the elderly and adults with chronic illnesses.

31 Oct 2009

Scientists present new perspective on antigenic drift of flu viruses

Influenza viruses evade infection-fighting antibodies by constantly changing the shape of their major surface protein. This shape-shifting, called antigenic drift, is why influenza vaccines-which are designed to elicit antibodies matched to each year's circulating virus strains-must be reformulated annually.

30 Oct 2009

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

A collaborative research team from the Uniformed Services University of the Health Sciences (USU), the Australian Animal Health Laboratory (AAHL), and the National Cancer Institute (NCI), National Institutes of Health (NIH) reports a major step forward in the development of an effective therapy against two deadly viruses, Nipah virus and the related Hendra virus.

30 Oct 2009

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

The La Jolla Institute for Allergy & Immunology, an international leader in immunology research and San Diego's only research institute focused solely on immune-mediated diseases, today will dedicate its new Elam Discovery Wall and Type 1 Diabetes Center, which will focus on research into novel immunological-focused approaches to type 1 diabetes.

30 Oct 2009

Women more likely to suffer from adverse drug reactions than men; proactive approach may help reduce problems

Most people have taken a prescription medication at one time or another, but according to a report from the Agency of Healthcare Research and Quality (AHRQ) in Rockville, Md., not only do women take more medications during their lifetimes, women are more likely to suffer from adverse drug events than men.

30 Oct 2009

Impact of wellness programs on pharmaceutical, diagnostic and device markets

MarketResearch.com has announced the addition of Kalorama Information's new report, "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets," to their collection of Healthcare market reports.

29 Oct 2009

NIH awards contract to LRRI for anthrax research

Lovelace Respiratory Research Institute (LRRI) was recently awarded a contract to continue research due to the potential for bioterrorist attacks involving Bacillus anthracis, the causative agent of anthrax, by the National Institutes of Allergy and Infectious Disease (NIAID), a division of the National Institutes of Health (NIH).

29 Oct 2009

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Perhaps the most comprehensive, multi-institutional study yet of the sexually transmitted bacteria chlamydia is under way at the University of Maryland, Baltimore (UMB).

29 Oct 2009

Toxic chemicals in face paints can cause skin sensitization and contact dermatitis

Ghosts and goblins aren't the only spooky things lurking around this Halloween. A new report by the Campaign for Safe Cosmetics reveals that popular children's face paints contain lead, a potent neurotoxin, as well as nickel, cobalt and chromium, which can cause lifelong skin sensitization and contact dermatitis.

28 Oct 2009

Starting Grant from ERC to LMU junior researchers

Two junior researchers from Ludwig-Maximilians-Universit-t (LMU) in Munich shall each receive a Starting Grant from the European Research Council (ERC). Professor Jens Michaelis, Department of Chemistry and Biochemistry, and Privatdozent Dr. David V-hringer, Institute of Immunology, shall receive grants amounting to 1.4 and 1.7 million Euros over five years. With its Starting Grant, the ERC supports highly creative researchers in order to encourage pioneering frontier research.

27 Oct 2009

Dey Pharma launches EpiPen Auto-Injector

Dey Pharma, L.P., a subsidiary of Mylan Inc., today launched a newly designed, patient-friendly EpiPen® Auto-Injector 0.3/0.15 mg. This next-generation EpiPen Auto-Injector maintains the simplicity, speed, safety and reliability of EpiPen Auto-Injector with several new, user-friendly features, including being the only auto-injector with needle-protection before and after use.

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

Modified NAGA: New enzyme for enzyme replacement therapy

A new study uses a creative structure-based remodeling strategy to design a therapeutic protein that exhibits significant advantages over currently available treatments for a rare disease that often leads to cardiac and renal failure. The research, published by Cell Press on October 22nd in the American Journal of Human Genetics, describes a new and highly promising candidate for enzyme replacement therapy (ERT) for Fabry disease.

23 Oct 2009

Tips to prevent allergy during Halloween

The haunted happenings of Halloween are upon us and soon we'll be carving pumpkins, dressing in costumes and telling spooky stories. But if your child has a food allergy, what's at the bottom of his or her trick-or-treat bag may be more frightening than any ghost or goblin.

23 Oct 2009

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Aeolus Pharmaceuticals, Inc. announced today that recent experiments in preclinical models conducted by the National Institutes of Health’s (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasure Development program have shown that AEOL 10150 can effectively increase regeneration of gastro-intestinal (GI) stem cells, reduce the severity and duration of diarrhea and improve survival when administered at 24 hours after doses of total-body irradiation that produce the lethal GI syndrome.

23 Oct 2009

Allergies News and Research

Latest Allergies News and Research

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

LRI and lupus organizations congratulate HGS and GlaxoSmithKline for achieving historical landmark

Scientists report a major step forward in the development of an effective therapy against Nipah virus

New tools and interventions can help in eradicating malaria

Study indicates possibility of a vaccine to prevent Group B Streptococcus infection

Scientists present new perspective on antigenic drift of flu viruses

Research team reports advances in development of an effective therapy against the Nipah and Hendra virus

La Jolla Institute dedicates new Elam Discovery Wall and Type 1 Diabetes Center

Women more likely to suffer from adverse drug reactions than men; proactive approach may help reduce problems

Impact of wellness programs on pharmaceutical, diagnostic and device markets

NIH awards contract to LRRI for anthrax research

$12.2 million grant from NIH for research on the sexually transmitted bacteria chlamydia

Toxic chemicals in face paints can cause skin sensitization and contact dermatitis

Starting Grant from ERC to LMU junior researchers

Dey Pharma launches EpiPen Auto-Injector

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Modified NAGA: New enzyme for enzyme replacement therapy

Tips to prevent allergy during Halloween

AEOL 10150 increases regeneration of GI stem cells: NIAID study results

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Allergies News and Research

Latest Allergies News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in